Eiger BioPharmaceuticals Inc.

6.24+0.1400+2.30%Vol 1.01M1Y Perf -32.52%
Jun 24th, 2022 16:00 DELAYED
BID4.84 ASK6.79
Open6.15 Previous Close6.10
Pre-Market- After-Market6.24
 - -  - -%
Target Price
26.00 
Analyst Rating
Strong Buy 1.00
Potential %
316.67 
Finscreener Ranking
★★+     47.13
Insiders Trans % 3/6/12 mo.
-/-100/-100 
Value Ranking
     41.63
Insiders Value % 3/6/12 mo.
-/-100/-100 
Growth Ranking
★+     43.16
Insiders Shares Cnt. % 3/6/12 mo.
-/-100/-100 
Income Ranking
 —    -
Price Range Ratio 52W %
41.75 
Earnings Rating
Buy
Market Cap269.67M 
Earnings Date
4th Aug 2022
Alpha0.01 Standard Deviation0.23
Beta1.57 

Today's Price Range

6.146.49

52W Range

3.5310.02

5 Year PE Ratio Range

-2.50-1.00

Summary:

Neutral

Technical Indicators: Neutral
Moving Averages: Neutral
Performance
1 Week
10.64%
1 Month
-3.26%
3 Months
-35.93%
6 Months
17.29%
1 Year
-32.52%
3 Years
-41.79%
5 Years
-10.22%
10 Years
-

TickerPriceChg.Chg.%
EIGR6.240.14002.30
AAPL141.663.39002.45
GOOG2 370.76117.07005.19
MSFT267.708.84003.41
XOM86.901.69001.98
WFC40.762.86007.55
JNJ182.292.63001.46
FB196.640.99000.51
GE67.083.01004.70
JPM117.323.40002.98
Financial StrengthValueIndustryS&P 500US Markets
3.70
4.00
0.17
0.34
-23.10
Leverage Ratio 1.60
ProfitabilityValueIndustryS&P 500US Markets
92.80
-735.90
-728.70
-
-35.57
RevenueValueIndustryS&P 500US Markets
11.17M
0.26
-
-
Earnings HistoryEstimateReportedSurprise %
Q01 2022-0.66-0.643.03
Q04 2021-0.67-0.644.48
Q03 2021-0.58-0.65-12.07
Q02 2021-0.54-0.57-5.56
Q01 2021-0.51-0.493.92
Q04 20200.33-0.58-275.76
Q03 2020-0.60-0.5213.33
Q02 2020-0.75-0.6020.00
Earnings Per EndEstimateRevision %Trend
6/2022 QR-0.711.39Positive
9/2022 QR-0.701.41Positive
12/2022 FY-2.321.69Positive
12/2023 FY-1.61-42.48Negative
Next Report Date4th Aug 2022
Estimated EPS Next Report-0.71
Estimates Count1
EPS Growth Next 5 Years %-
Volume Overview
Volume1.01M
Shares Outstanding43.22K
Shares Float35.71M
Trades Count6.15K
Dollar Volume6.29M
Avg. Volume422.15K
Avg. Weekly Volume364.52K
Avg. Monthly Volume344.74K
Avg. Quarterly Volume557.17K

Eiger BioPharmaceuticals Inc. (NASDAQ: EIGR) stock closed at 6.24 per share at the end of the most recent trading day (a 2.3% change compared to the prior day closing price) with a volume of 1.01M shares and market capitalization of 269.67M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 29 people. Eiger BioPharmaceuticals Inc. CEO is David Cory.

The one-year performance of Eiger BioPharmaceuticals Inc. stock is -32.52%, while year-to-date (YTD) performance is 20.23%. EIGR stock has a five-year performance of -10.22%. Its 52-week range is between 3.53 and 10.0213, which gives EIGR stock a 52-week price range ratio of 41.75%

Eiger BioPharmaceuticals Inc. currently has a PE ratio of -2.30, a price-to-book (PB) ratio of 2.51, a price-to-sale (PS) ratio of 21.82, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of -52.19%, a ROC of -58.08% and a ROE of -76.80%. The company’s profit margin is -35.57%, its EBITDA margin is -728.70%, and its revenue ttm is $11.17 Million , which makes it $0.26 revenue per share.

Of the last four earnings reports from Eiger BioPharmaceuticals Inc., there were 2 positive earnings surprise and 2 negative earnings surprise. The company has EPS estimate of $-0.71 for the next earnings report. Eiger BioPharmaceuticals Inc.’s next earnings report date is 04th Aug 2022.

The consensus rating of Wall Street analysts for Eiger BioPharmaceuticals Inc. is Strong Buy (1), with a target price of $26, which is +316.67% compared to the current price. The earnings rating for Eiger BioPharmaceuticals Inc. stock is Buy (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Eiger BioPharmaceuticals Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

Eiger BioPharmaceuticals Inc. has a Neutral technical analysis rating based on Technical Indicators (ADX : 16.09, ATR14 : 0.47, CCI20 : 39.17, Chaikin Money Flow : -0.07, MACD : -0.24, Money Flow Index : 65.70, ROC : 1.96, RSI : 52.01, STOCH (14,3) : 71.43, STOCH RSI : 1.00, UO : 54.73, Williams %R : -28.57), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Eiger BioPharmaceuticals Inc. in the last 12-months were: Eldon C. Mayer (Sold 3 217 shares of value $16 997 ), Sriram Ryali (Sold 2 266 shares of value $12 683 )

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
3 (100.00 %)
3 (100.00 %)
3 (100.00 %)
Moderate Buy
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Hold
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Summary RatingStrong Buy
1.00
Strong Buy
1.00
Strong Buy
1.00

Eiger BioPharmaceuticals Inc.

Eiger BioPharmaceuticals Inc is a late-stage biopharmaceutical company focused on the development and commercialization of drugs for serious, rare and ultra-rare diseases with high unmet medical needs and no approved therapies. Its program lonafarnib, a prenylation inhibitor, boosted with ritonavir, for the treatment of Hepatitis Delta Virus (HDV) infection, is in Phase 3 clinical development. Its product candidate pipeline includes Lonafarnib (LNF) in HDV, Peginterferon Lambda (lambda) in HDV, LNF in Progeria and Progeroid Laminopathies (PL), Avexitide in Post-Bariatric Hypoglycemia (PBH), and Avexitide in Congenital Hyperinsulinism (CHI), all advancing toward Phase 3.

CEO: David Cory

Telephone: +1 650 272-6138

Address: 2155 Park Boulevard, Palo Alto 94306, CA, US

Number of employees: 29

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

67%33%

Bearish Bullish

67%33%

Bearish Bullish

63%37%

TipRanks News for EIGR

Wed, 04 May 2022 03:27 GMT Eiger Biopharmaceuticals (EIGR) Gets a Buy Rating from Robert W. Baird

- TipRanks. All rights reserved.

Thu, 17 Mar 2022 17:15 GMT Eiger Biopharmaceuticals (EIGR) Gets a Buy Rating from Ladenburg Thalmann & Co.

- TipRanks. All rights reserved.

Sat, 12 Mar 2022 03:52 GMT Analysts Are Bullish on Top Healthcare Stocks: Eiger Biopharmaceuticals (EIGR), Geron (GERN)

- TipRanks. All rights reserved.

News

Stocktwits